171 related articles for article (PubMed ID: 21212425)
1. Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy.
Shao YY; Lu LC; Cheng AL; Hsu CH
Oncologist; 2011; 16(1):82-6. PubMed ID: 21212425
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy.
Lu LC; Shao YY; Chan SY; Hsu CH; Cheng AL
Anticancer Res; 2014 Feb; 34(2):1047-52. PubMed ID: 24511053
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.
Taketomi A
Int J Clin Oncol; 2016 Apr; 21(2):213-218. PubMed ID: 26899258
[TBL] [Abstract][Full Text] [Related]
4. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.
Tanaka S; Arii S
Int J Clin Oncol; 2006 Apr; 11(2):82-9. PubMed ID: 16622743
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeted therapies in hepatocellular carcinoma.
Tanaka S; Arii S
Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
9. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
11. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of hepatocellular carcinoma with extrahepatic metastases.
Natsuizaka M; Omura T; Akaike T; Kuwata Y; Yamazaki K; Sato T; Karino Y; Toyota J; Suga T; Asaka M
J Gastroenterol Hepatol; 2005 Nov; 20(11):1781-7. PubMed ID: 16246200
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle Delivery of MnO
Chang CC; Dinh TK; Lee YA; Wang FN; Sung YC; Yu PL; Chiu SC; Shih YC; Wu CY; Huang YD; Wang J; Lu TT; Wan D; Chen Y
ACS Appl Mater Interfaces; 2020 Oct; 12(40):44407-44419. PubMed ID: 32865389
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
16. Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor.
Han MS; Moon KS; Lee KH; Cho SB; Lim SH; Jang WY; Jung TY; Kim IY; Jung S
BMC Cancer; 2013 Dec; 13():567. PubMed ID: 24289477
[TBL] [Abstract][Full Text] [Related]
17. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
18. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
Abou-Alfa GK; Venook AP
Lancet Oncol; 2013 Jun; 14(7):e283-8. PubMed ID: 23725711
[TBL] [Abstract][Full Text] [Related]
19. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.
Raoul JL; Gilabert M; Adhoute X; Edeline J
Expert Opin Pharmacother; 2017 Oct; 18(14):1467-1476. PubMed ID: 28893090
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.
Uchino K; Tateishi R; Shiina S; Kanda M; Masuzaki R; Kondo Y; Goto T; Omata M; Yoshida H; Koike K
Cancer; 2011 Oct; 117(19):4475-83. PubMed ID: 21437884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
